You searched for biosimilars - Permanente Medicine

Dr. Awsare: Biosimilars in an integrated model help lower drug costs

Sameer Awsare, MD, tells Pink Sheet that Kaiser Permanente’s unique integrated structure helps it succeed in adopting biosimilars, resulting in lower drug costs for patients without sacrificing safety and efficacy.

Sameer Awsare, MD, discusses Permanente perspective on biosimilars

Sameer Awsare, MD, associate executive director for The Permanente Medical Group, shared in Biosimilars Development how Kaiser Permanente is a leader in the use of biosimilars.

Sameer Awsare, MD, highlights Kaiser Permanente model in case for biosimilars market

Physician leader Sameer Awsare, MD, FACP, co-writes an article in Health Affairs encouraging competition in the biosimilar drugs market to help curb rising health care costs.

Sameer Awsare, MD, focuses on Kaiser Permanente’s innovative approach to biosimilars at GRx+Biosims

Presenting at this week’s GRx+Biosims meeting in North Bethesda, Maryland, Sameer Awsare, MD, associate executive director of The Permanente Medical Group, elaborated on how Kaiser Permanente leverages its integrated care model to drive collaboration in advancing the move to biosimilars.

Sameer Awsare, MD, breaks down the basics of biosimilars

During a public briefing at the Alliance for Health Policy, Sameer Awsare, MD, of The Permanente Medical Group, joined other health care leaders to explain the mechanisms of biosimilar drugs.

Value-based care: A win-win for older adults, care systems

Ramin Davidoff, MD, on value-based care and how it benefits older adults.

Driving health care innovation in 10 steps

Our care model

Tweetcap: U.S. Chamber of Commerce’s 2019 Health Care Summit spotlights business of health

The U.S. Chamber of Commerce hosted its 2019 Health Care Summit, "The Business of Health: Transforming with Transparency," in Washington, D.C. on Thursday, October 31.

The price is wrong

Sameer Awsare, MD, associate executive director at The Permanente Medical Group, addresses the need to curb prices on biologics to protect patients.